Floatz logo

Epoch-F/R

Hodgkins Lymphoma

National Cancer Institute (NCI)Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hodgkins Lymphoma cohort.

Asset / SponsorPhaseRating
PEGASPARGASE
Ciusss de L'Est de l'Île de Montréal
Phase 2B
Fludarabine
M.D. Anderson Cancer Center
Phase 2B
Zoladex
University of Cologne
Phase 2B
Inno-206
Milton S. Hershey Medical Center
Phase 2CCC
Ebv Ctl'S
New York Medical College
Phase 1CC

View all 9 →

Same molecule, other indications

Epoch-F/R is also rated in:

Non-Hodgkins LymphomaDormant
CC
Indicative ·
43 / 100
View asset →
MDSDormant
CC
Indicative ·
41 / 100
View asset →
LeukemiaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →